about
Mutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing MutationsBroad-spectrum agents for flaviviral infections: dengue, Zika and beyondEstablishment and Application of a High Throughput Screening System Targeting the Interaction between HCV Internal Ribosome Entry Site and Human Eukaryotic Translation Initiation Factor 3.A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compoundEffects of HIV-1 gp41-Derived Virucidal Peptides on Virus-like Lipid Membranes.Polymers in the Delivery of siRNA for the Treatment of Virus Infections.Cyclin-dependent kinases as therapeutic targets for HIV-1 infection.Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015).An update: Epstein-Barr virus and immune evasion via microRNA regulation.Evaluation of Sofosbuvir (β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine) as an inhibitor of Dengue virus replication.Escape of tick-borne flavivirus from 2' -C-methylated nucleoside antivirals is mediated by a single conservative mutation in NS5 that has a dramatic effect on viral fitness.Fate-Regulating Circuits in Viruses: From Discovery to New Therapy Targets.Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections.Fluorination of Naturally Occurring N⁶-Benzyladenosine Remarkably Increased Its Antiviral Activity and Selectivity.Reactive Oxygen Species-Regulating Polymersome as an Antiviral Agent against Influenza Virus.Discovery and Mechanistic Study of Benzamide Derivatives That Modulate Hepatitis B Virus Capsid Assembly.Guanine α-carboxy nucleoside phosphonate (G-α-CNP) shows a different inhibitory kinetic profile against the DNA polymerases of human immunodeficiency virus (HIV) and herpes viruses.Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.Antiviral screening identifies adenosine analogs targeting the endogenous dsRNA Leishmania RNA virus 1 (LRV1) pathogenicity factor.No longer 'written off' - times have changed for the BBV-infected dental professional.Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2).Next-Generation Sequencing: a Diagnostic One-Stop Shop for Hepatitis C?Current landscape and future prospects of antiviral drugs derived from microbial products.NLRX1 mediates MAVS degradation to attenuate hepatitis C virus-induced innate immune response through PCBP2.Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins.Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses.Induction of Apoptosis and Subsequent Phagocytosis of Virus-Infected Cells As an Antiviral Mechanism.Modular cell-based platform for high throughput identification of compounds that inhibit a viral interferon antagonist of choice.Reversible Self-Assembled Monolayers (rSAMs): Adaptable Surfaces for Enhanced Multivalent Interactions and Ultrasensitive Virus Detection.Basic fibroblast growth factor protects against influenza A virus-induced acute lung injury by recruiting neutrophils.Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors.Cadherin 6 is activated by Epstein-Barr virus LMP1 to mediate EMT and metastasis as an interplay node of multiple pathways in nasopharyngeal carcinoma.Structural and Functional Basis of the Fidelity of Nucleotide Selection by Flavivirus RNA-Dependent RNA Polymerases.Small Molecules and Antibodies for Zika Therapy.Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo.Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism.Adoptive Immunotherapy of Viral Infections: Should Infectious Disease Embrace Cellular Immunotherapy?Synthesis and antiviral evaluation of base-modified deoxythreosyl nucleoside phosphonates.Simple In Vitro Assay To Evaluate the Incorporation Efficiency of Ribonucleotide Analog 5'-Triphosphates into RNA by Human Mitochondrial DNA-Dependent RNA Polymerase.Evaluation of ODE-Bn-PMEG, an acyclic nucleoside phosphonate prodrug, as an antiviral against productive HPV infection in 3D organotypic epithelial cultures.
P2860
Q28072953-1BA098BA-4A81-4D0E-8A84-3399C92A63F6Q29994527-B48CF2B6-089B-4FD1-8B66-3094C2763FD8Q33734868-93EF8C29-BA4F-4BA1-8156-38C230A8C6D1Q33918841-770DA90E-3C51-4E12-AC27-C8FACD3A1C05Q38630012-8F75ABF9-D278-4004-9C67-615A15B8E009Q38889573-EEAFDA99-0C0D-4F5F-8216-9CDCC93A5DCCQ38995028-C8BF1BF7-A9B1-4764-A437-D6EF4A1BB39FQ39038238-B2143FEF-8B41-4DAB-B379-A09E3B7AFEEAQ39409293-9CFE6B40-9468-4D95-895F-88CF27228F0EQ40046618-BA2B0A0F-4DDA-4A14-BE54-4516EE3A9AB5Q40080931-16D5858F-242A-4006-8D1A-7BDF9B9510E4Q40086009-370B43F5-EF09-4AEF-BD00-8DC0CF087E91Q40105941-37BEBB97-8DF3-47A5-A423-DAA8BD3B7F7BQ40115312-2E4A5642-4A93-49D3-A89D-6D10AF76BB41Q40129147-541AC6D6-ED78-4643-A128-10408E4DF487Q40178518-F949B985-B34B-4616-8627-499111A6A712Q40251943-E41630CF-D371-4C70-882D-0AF023EAE1A4Q40261719-2BFFF621-0D68-4B89-91C9-0A2AA355DE55Q40368500-1516C196-8A77-484A-B209-FE91B0C87550Q40373187-E2B3B80D-7BD2-4B9F-908E-BB2CE2CAA929Q40447961-2C2C9592-B9E8-44F1-9FC6-3F18D49219EEQ40627402-72BA0799-1C05-49BE-B746-23D10B059A7BQ41919714-AEDD8B82-D4A5-4777-AC4D-C47B0A57F80DQ41928800-0A927512-7C18-4B3D-86A3-B1D96715D3ADQ41930599-8E48A95C-6BE9-4794-B3E5-656A1FB9DD01Q41930666-7BEB1999-7FFF-46FA-AF8F-1975560C3665Q42369080-462B714E-91B1-4B3D-BAF9-CC1B0B47E6FCQ42542221-7D91C1A4-D0E4-4429-BC8E-7140B0DD345AQ45323845-ADE40498-3DF5-4397-BF6A-E635507F98F5Q45325042-F48F55C7-1991-4B93-943D-4A3397163AFBQ45325372-F381166F-4113-42F6-A273-5D7AAF1E23F9Q47248660-F48AB2F6-EE6E-4ABE-A5C6-0048A829ED98Q47547559-4BE242BF-0A37-4EC3-AAA3-BBBF2FA2B806Q47558373-EF0A07AF-BADA-4821-9D21-62A870AA513FQ47558474-C7F5FDF6-F2E9-4D29-9A14-E6AF0E7D1FD6Q47564328-75FDBF16-D2BD-473A-B49A-1CDC547DC37DQ47613802-73DB31D7-46E8-4EE7-BC51-0E829AE9A5BEQ48752998-67B9F9F5-4D12-4D52-A618-98685B892582Q49185722-C48DD626-8EA0-490C-94B4-B6AF2A263E86Q49487328-D6C29B4D-7B6C-48E2-AD0D-34D555C8C035
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Approved Antiviral Drugs over the Past 50 Years
@ast
Approved Antiviral Drugs over the Past 50 Years
@en
Approved Antiviral Drugs over the Past 50 Years
@nl
type
label
Approved Antiviral Drugs over the Past 50 Years
@ast
Approved Antiviral Drugs over the Past 50 Years
@en
Approved Antiviral Drugs over the Past 50 Years
@nl
prefLabel
Approved Antiviral Drugs over the Past 50 Years
@ast
Approved Antiviral Drugs over the Past 50 Years
@en
Approved Antiviral Drugs over the Past 50 Years
@nl
P2860
P3181
P356
P1476
Approved Antiviral Drugs over the Past 50 Years
@en
P2093
Guangdi Li
P2860
P304
P3181
P356
10.1128/CMR.00102-15
P407
P577
2016-07-01T00:00:00Z